Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 17/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 17/20 | 0.48 |
| ▸ | GSPT1 | P15170 | 3/20 | 0.39 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18843832 | 0.86 | DDB1 (0.44) | DDB1CRBNGSPT1IKZF3CYP2C19 | |
| SCHEMBL24113826 | 0.80 | DDB1 (0.43) | DDB1CRBNGSPT1BRD4CYP2C19 | |
| SCHEMBL25213150 | 0.79 | CRBN (0.54) | DDB1CRBNGSPT1IKZF3BRD4 | |
| SCHEMBL24113885 | 0.76 | CRBN (0.41) | DDB1CRBNIKZF3 | |
| SCHEMBL13881351 | 0.75 | CRBN (0.51) | DDB1CRBNGSPT1IKZF3BRD4 | |
| SCHEMBL21069882 | 0.75 | CRBN (0.73) | DDB1CRBNGSPT1IKZF3 | |
| SCHEMBL24597653 | 0.74 | DDB1 (0.43) | DDB1CRBNGSPT1BRD4CREBBP | |
| SCHEMBL31028610 | 0.74 | DDB1 (0.43) | DDB1CRBNGSPT1BRD4CREBBP | |
| SCHEMBL29750605 | 0.74 | DDB1 (0.43) | DDB1CRBNGSPT1BRD4CREBBP | |
| SCHEMBL3656297 | 0.74 | DDB1 (0.57) | DDB1CRBNGSPT1IKZF3BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10034872-B2 | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies | CELGENE CORPORATION (US) | 2018-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10034872-B2 | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies | CHP1, MCL1, CSGALNACT1 | DDB1 233/4885CRBN 54/4885GSPT1 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.